Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | DVL1 | O14640 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605485 | 0.86 | AKR1C3 (0.49) | MRGPRX4KDM4EPKM | |
| SCHEMBL4606969 | 0.85 | DVL1 (0.56) | DVL1MAPTHTTKDM4EPKM | |
| SCHEMBL1824515 | 0.84 | KDM4E (0.46) | MRGPRX4NR4A2DVL1MAPTHTT | |
| SCHEMBL4605146 | 0.82 | DVL1 (0.52) | NR4A2DVL1FFAR1KDM4EPKM | |
| SCHEMBL1825703 | 0.82 | FFAR1 (0.46) | MRGPRX4DVL1MAOBFFAR1KDM4E | |
| SCHEMBL1827099 | 0.82 | MRGPRX4 (0.58) | MRGPRX4MAPTKDM4EPLK1PKM | |
| SCHEMBL1824032 | 0.82 | FFAR1 (0.52) | MRGPRX4DVL1MAOBFFAR1KDM4E | |
| SCHEMBL1827561 | 0.82 | RXRA (0.60) | MRGPRX4MAPTKDM4EPLK1PKM | |
| SCHEMBL1826068 | 0.82 | KDM4E (0.46) | MRGPRX4NR4A2DVL1FFAR1KDM4E | |
| SCHEMBL1826571 | 0.81 | MRGPRX4 (0.46) | MRGPRX4DVL1MAOBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720825-B1 | ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS | ACTIVE BIOTECH AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-7074831-B2 | Compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | MALT1, TPMT, FUCA1 | MRGPRX4 420/4885NR4A2 1796/4885DVL1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.